KBC Group
CLVS

KBC Group’s Clovis Oncology, Inc. CLVS Stock Holding History

KBC Group’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-12,713
Closed -$133K – 1490
2019
Q4 		$133K Sell
12,713
-41,271
-76% -$300K ﹤0.01% 1333
2019
Q3 		$212K Buy
53,984
+40,693
+306% +$329K ﹤0.01% 1243
2019
Q2 		$198K Hold
13,291
– – ﹤0.01% 1228
2019
Q1 		$330K Sell
13,291
-302,667
-96% -$7.59M ﹤0.01% 1172
2018
Q4 		$5.67M Buy
315,958
+74,229
+31% +$1.52M 0.06% 322
2018
Q3 		$7.1M Buy
241,729
+148,227
+159% +$5.74M 0.05% 357
2018
Q2 		$4.25M Buy
93,502
+5,339
+6% +$260K 0.04% 440
2018
Q1 		$4.66M Buy
88,163
+31,151
+55% +$1.82M 0.04% 394
2017
Q4 		$3.88M Buy
57,012
+16,343
+40% +$1.14M 0.03% 447
2017
Q3 		$3.35M Sell
40,669
-13,420
-25% -$1.06M 0.03% 476
2017
Q2 		$5.06M Buy
+54,089
New +$3.31M 0.05% 367
2014
Q1 		– Sell
-6,437
Closed -$388K – 1357
2013
Q4 		$388K Buy
+6,437
New +$350K 0.01% 879

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

KBC Group's CLVS Position: Q1 2020 in Review

KBC Group sold out of Clovis Oncology, Inc. (CLVS) in Q1 2020, closing a stake of 12,713 shares — an estimated $133K sold.

KBC Group first reported a position in CLVS in Q4 2013 and held it in 12 quarters. The position peaked at $7.1M in Q3 2018. 154 funds tracked by Wall St. Rank hold CLVS as of Q1 2020.

  • KBC Group reported no remaining Clovis Oncology, Inc. position as of Q1 2020 after selling out during the quarter.
  • KBC Group sold 12,713 Clovis Oncology, Inc. shares in Q1 2020, an estimated $133K.
  • KBC Group first reported a position in Clovis Oncology, Inc. in Q4 2013 and held it in 12 quarters.
  • KBC Group's Clovis Oncology, Inc. position peaked at $7.1M in Q3 2018.
  • 154 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2020.

Based on KBC Group's 13F filing for Q1 2020, filed 4 May 2020.